Olivier Gout

Amiens, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 92 publications

Multiple sclerosis reactivations after fingolimod discontinuation for pregnancy planning.

Multiple sclerosis reactivations after fingolimod discontinuation for pregnancy planning.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: July 09, 2024

Natalizumab extended-interval dosing in a real-life setting.

Natalizumab extended-interval dosing in a real-life setting.

Journal: Journal of the neurological sciences

Published: March 23, 2023

Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system.

Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 14, 2022

High diagnostic accuracy of T2FLAIR at 3 T in the detection of optic nerve head edema in acute optic neuritis.

High diagnostic accuracy of T2FLAIR at 3 T in the detection of optic nerve head edema in acute optic neuritis.

Journal: European radiology

Published: December 04, 2022

Generalization of ocular myasthenia gravis 10 years after onset.

Generalization of ocular myasthenia gravis 10 years after onset.

Journal: Journal of neurology

Published: May 19, 2022

Prospective longitudinal study on prognostic factors of visual recovery and structural change after a first episode of optic neuritis.

Prospective longitudinal study on prognostic factors of visual recovery and structural change after a first episode of optic neuritis.

Journal: European journal of neurology

Published: March 02, 2022

Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.

Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: February 07, 2022

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.

Journal: BMC medical research methodology

Published: January 14, 2022

Human pegivirus identified in severe myelitis and optic neuritis in immunocompromised patients: A pathogenic role for a forgotten virus?

Human pegivirus identified in severe myelitis and optic neuritis in immunocompromised patients: A pathogenic role for a forgotten virus?

Journal: Revue neurologique

Published: January 05, 2022

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.

Journal: Neurology

Published: November 05, 2021

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.

Journal: CNS drugs

Published: August 16, 2021

Vascular origin in acute transient visual disturbance: A prospective study.

Vascular origin in acute transient visual disturbance: A prospective study.

Journal: European journal of neurology

Published: June 29, 2021

Showing 1-12 of 92

Last Updated: 09/26/2026